|
|
|||||||||||||||||||
With over 20,000 new cases of multiple myeloma and associated types of cancer expected to be diagnosed each year in the USA alone, this is one of the key drivers for the future growth of our business. Considered almost untreatable only 20 years ago, huge strides have been made in the successful treatment of multiple myeloma with new drugs becoming available and new treatment regimes being assessed. Freelite has been used as a sensitive marker for the efficacy of some of these newer treatments and has helped clinicians gain a clear understanding of how some of these drugs are benefiting their patients. Furthermore, with numerous different therapies now available, treatment decisions which may have taken weeks or months can now be made in days thanks to the availability of sensitive and reliable results using Freelite. National and International guidelines for the diagnosis and treatment of multiple myeloma and associated cancers now include Freelite results as a requirement for the initial screening and monitoring the treatment of patients. Numerous clinical trials are underway to look at the use of Freelite in a range of other malignancies as well as how the results may radically change the management of complications such as renal disease in cancer patients. There are currently approximately 3.3 million pairs of Freelite tests performed annually worldwide with the number of analyses increasing at a rate of around 30% per year.
An important step allowing access to Freelite across all clinical laboratories was the introduction of the SPAplus Specialized Protein Analyzer, optimized for running Freelite and other high sensitivity special protein assays.
Products used for the detection of immunodeficiency
These include the inherited or acquired disorders of the immune system and products used in donor selection and manufacture of vaccines. Binding Site has been and remains a market leader in products for the investigation of these diseases. New applications in the biotechnology sector have ensured the continued growth of this product range.
An important step allowing access to Freelite across all clinical laboratories was the introduction of the SPAplus Specialized Protein Analyzer, optimized for running Freelite and other high sensitivity special protein assays.
Products used for the detection of immunodeficiency
These include the inherited or acquired disorders of the immune system and products used in donor selection and manufacture of vaccines. Binding Site has been and remains a market leader in products for the investigation of these diseases. New applications in the biotechnology sector have ensured the continued growth of this product range.
